COVID-19 updates - Get the latest information about Coronavirus and Iowa Heart Center

Optimize

Purpose of Study

Assess the safety and efficacy of the Svelte Sirolimus-Eluting Coronary Stent systems compared to the Xience or Promus Drug-Eluting Stent systems in subjects with less than 3 target lesions in up to 2 native coronary artery vessels

Trial Status

In follow up

Eligibility Criteria

Have symptomtic coronary artery disease with evidence of ischemia, have up to 3 target lesions in up to 2 native coronary artery vessels

Duration of Participation

Approximately 5 years

Contact Name: Lindsay Risk

Contact Phone: 515-633-3847

Contact Email: lirisk@iowaheart.com